Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10037156 | 0.92 | MEN1 (0.50) | MEN1KMT2AGAATDP1TSHR | |
| SCHEMBL1082707 | 0.91 | TDP1 (0.56) | MEN1KMT2AGAATDP1TSHR | |
| SCHEMBL25461951 | 0.91 | MEN1 (0.45) | MEN1KMT2AGAATDP1TSHR | |
| SCHEMBL23034976 | 0.91 | MEN1 (0.45) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL10037160 | 0.88 | MEN1 (0.49) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL6478259 | 0.88 | KMT2A (0.49) | MEN1KMT2AGAATDP1TSHR | |
| SCHEMBL10037287 | 0.87 | TDP1 (0.46) | MEN1KMT2AGAATDP1TSHR | |
| SCHEMBL25014915 | 0.84 | TDP1 (0.50) | MEN1KMT2AGAATDP1TSHR | |
| SCHEMBL14646688 | 0.84 | TDP1 (0.50) | MEN1KMT2AGAATDP1TSHR | |
| SCHEMBL1042383 | 0.84 | TDP1 (0.59) | MEN1KMT2AGAATDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466248-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | Sanofi (FR) | 2024-11-27 | — | — | EP | disclosed |
| CN-118829624-A | Lipid compound and use thereof | 赛诺菲 | 2024-10-22 | — | — | CN | disclosed |
| CN-118591560-A | Combination therapy for cancer | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20230375537-A1 | BASE MATERIAL FOR MANUFACTURING SENSOR FOR ANALYZING DETECTION OBJECT, SENSOR FOR ANALYZING DETECTION OBJECT, AND METHOD FOR ANALYZING DETECTION OBJECT | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230375537-A1 | BASE MATERIAL FOR MANUFACTURING SENSOR FOR ANALYZING DETECTION OBJECT, SENSOR FOR ANALYZING DETECTION OBJECT, AND METHOD FOR ANALYZING DETECTION OBJECT | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2023-11-23 | — | — | US | disclosed |
| WO-2023135305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | SANOFI (FR) | 2023-07-20 | — | — | WO | disclosed |
| US-20230152306-A1 | NANOPARTICLES FOR SENSING USE AND PRODUCTION METHOD FOR SAME | TearExo Inc. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230152306-A1 | NANOPARTICLES FOR SENSING USE AND PRODUCTION METHOD FOR SAME | TearExo Inc. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-10107798-B2 | Methods of chemotype evolution | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180238863-A1 | CHEMICAL SYNTHESIS | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-08-23 | — | — | US | disclosed |
| US-20110263514-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011116152-A2 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD -BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110118126-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118126-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118126-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2257637-A1 | METHODS OF CHEMOTYPE EVOLUTION | Sunesis Pharmaceuticals, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009120795-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009120795-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20080261831-A1 | Ligands and libraries of ligands | WELLS JIM | 2008-10-23 | — | — | US | disclosed |
| US-20080261831-A1 | Ligands and libraries of ligands | WELLS JIM | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263514-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SNRPE, SNRPF, SNRPA | MEN1 2561/4885KMT2A 3072/4885GAA 1918/4885 |
| US-20180238863-A1 | CHEMICAL SYNTHESIS | COASY, FASN, DHPS | MEN1 1215/4885KMT2A 1758/4885GAA 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.